Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Randy Schmid who wrote (1944)	9/30/1997 4:24:00 PM
From: Henry Niman	of 6136

Randy. AGPH has definitely done an excellent job of grabbing market share from the big boys. My background is on the scientific side, so that's what I have focused on. However, I'm sure that other other factors play a large role in the compliance area, which seems to be a major determinant for outcome. I'm still curious about a head to head comparision in vivo (naive patients would be the easiest group for comparisions). Have any of the big boys used their PI (on naive patients) and then asked if relapsed patients were susceptable to other PI's, including Viracept (AGPH seems to have done such a test for Viracept, with impressive results for naive patients).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next